243 related articles for article (PubMed ID: 19105705)
1. Anagrelide: 20 years later.
Emadi A; Spivak JL
Expert Rev Anticancer Ther; 2009 Jan; 9(1):37-50. PubMed ID: 19105705
[TBL] [Abstract][Full Text] [Related]
2. Anagrelide: analysis of long-term efficacy, safety and leukemogenic potential in myeloproliferative disorders.
Fruchtman SM; Petitt RM; Gilbert HS; Fiddler G; Lyne A;
Leuk Res; 2005 May; 29(5):481-91. PubMed ID: 15755500
[TBL] [Abstract][Full Text] [Related]
3. [Anagrelide in control of myeloproliferative thrombocythemia: long-term experiences in 6 patients].
Burkhard R; Adam H; Widmer L; Honegger HP
Schweiz Med Wochenschr; 1998 Nov; 128(46):1808-12. PubMed ID: 9857387
[TBL] [Abstract][Full Text] [Related]
4. Anagrelide for thrombocytosis in myeloproliferative disorders: a prospective study to assess efficacy and adverse event profile.
Steurer M; Gastl G; Jedrzejczak WW; Pytlik R; Lin W; Schlögl E; Gisslinger H
Cancer; 2004 Nov; 101(10):2239-46. PubMed ID: 15476273
[TBL] [Abstract][Full Text] [Related]
5. Anagrelide: a new drug for treating thrombocytosis.
Silverstein MN; Petitt RM; Solberg LA; Fleming JS; Knight RC; Schacter LP
N Engl J Med; 1988 May; 318(20):1292-4. PubMed ID: 3362187
[TBL] [Abstract][Full Text] [Related]
6. [Anagrelide in the treatment of essential thrombocythemia (ET) and other myeloproliferative disorders with thrombocythemia based on data from patient register in the CR].
Penka M; Doubek M; Schwarz J; Pytlík R; Dulícek P; Kissová J; Hlusí A; Vozobulová V; Cerná O; Brychtová Y; Szotkowski T; Volková Z; Seghetová J; Schutzová M; Hadacová I; Hochová I; Voglová J; Siroký O; Belada D; Lhot'anová T; Bubeník B; Vránová M; Micaníková M; Dusek L
Vnitr Lek; 2006 May; 52(5):498-503. PubMed ID: 16771099
[TBL] [Abstract][Full Text] [Related]
7. Adverse effects and benefits of two years of anagrelide treatment for thrombocythemia in chronic myeloproliferative disorders.
Birgegård G; Björkholm M; Kutti J; Lärfars G; Löfvenberg E; Markevärn B; Merup M; Palmblad J; Mauritzson N; Westin J; Samuelsson J
Haematologica; 2004 May; 89(5):520-7. PubMed ID: 15136214
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics, bioequivalence, tolerability, and effects on platelet counts of two formulations of anagrelide in healthy volunteers and patients with thrombocythemia associated with chronic myeloproliferation.
Petrides PE; Gisslinger H; Steurer M; Linkesch W; Krumpl G; Schüller A; Widmann R
Clin Ther; 2009 Feb; 31(2):386-98. PubMed ID: 19302911
[TBL] [Abstract][Full Text] [Related]
9. Anagrelide, a therapy for thrombocythemic states: experience in 577 patients. Anagrelide Study Group.
Am J Med; 1992 Jan; 92(1):69-76. PubMed ID: 1731512
[TBL] [Abstract][Full Text] [Related]
10. Anagrelide treatment in 52 patients with chronic myeloproliferative diseases.
Penninga E; Jensen BA; Hansen PB; Clausen NT; Mourits-Andersen T; Nielsen OJ; Hasselbalch HC
Clin Lab Haematol; 2004 Oct; 26(5):335-40. PubMed ID: 15485463
[TBL] [Abstract][Full Text] [Related]
11. Anagrelide: new drug. Essential thrombocythaemia: further evaluation needed for this last-resort treatment.
Prescrire Int; 2006 Jun; 15(83):83-6. PubMed ID: 16764090
[TBL] [Abstract][Full Text] [Related]
12. Anagrelide is effective in treating patients with hydroxyurea-resistant thrombocytosis in patients with chronic myeloid leukemia.
Silver RT
Leukemia; 2005 Jan; 19(1):39-43. PubMed ID: 15510207
[TBL] [Abstract][Full Text] [Related]
13. Role of anagrelide in the treatment of thrombocytosis.
Brooks WG; Stanley DD; Goode JV
Ann Pharmacother; 1999 Oct; 33(10):1116-8, 1121. PubMed ID: 10534225
[TBL] [Abstract][Full Text] [Related]
14. Precipitous fall in platelet count with anagrelide: case report and critique of dosing recommendations.
McCune JS; Liles D; Lindley C
Pharmacotherapy; 1997; 17(4):822-6. PubMed ID: 9250565
[TBL] [Abstract][Full Text] [Related]
15. [Anagrelide in the treatment of thrombocythemia essential (ET)].
Mazur G; Wróbel T; Podolak-Dawidziak M; Kuliszkiewicz-Janus M; Potoczek S; Nosol J; Kuliczkowski K
Pol Arch Med Wewn; 2004 Dec; 112(6):1445-50. PubMed ID: 15962609
[TBL] [Abstract][Full Text] [Related]
16. Anagrelide for control of thrombocytosis due to myeloproliferative disorders.
Harrison CN
Future Oncol; 2005 Oct; 1(5):609-18. PubMed ID: 16556037
[TBL] [Abstract][Full Text] [Related]
17. Thrombocytosis--report of a case.
Thomas M; Pavithran K; Salil ; Somarajan A
J Assoc Physicians India; 2000 Apr; 48(4):441-2. PubMed ID: 11273186
[TBL] [Abstract][Full Text] [Related]
18. Anagrelide for treatment of patients with chronic myelogenous leukemia and a high platelet count.
Trapp OM; Beykirch MK; Petrides PE
Blood Cells Mol Dis; 1998 Mar; 24(1):9-13. PubMed ID: 9516377
[TBL] [Abstract][Full Text] [Related]
19. [Anagrelide--a new drug to reduce platelets in myeloproliferative diseases].
Bennett M
Harefuah; 1999 May; 136(9):717-20. PubMed ID: 10955097
[No Abstract] [Full Text] [Related]
20. [Anagrelide--new antiplatelet drug].
Robak T; Treliński J; Hołub A
Acta Haematol Pol; 1994; 25(4):309-15. PubMed ID: 7847031
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]